Glazer Capital LLC’s Ibere Pharmaceuticals IBER Stock Holding History

Glazer Capital LLC’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,330,102	Closed	-$13.4M	–	520
2022 Q4	$13.4M	Buy	1,330,102 +243,601	+22%	+$2.44M	0.35%	105
2022 Q3	$10.8M	Buy	1,086,501 +576,567	+113%	+$5.69M	0.2%	162
2022 Q2	$5M	Buy	509,934 +331,439	+186%	+$3.25M	0.12%	235
2022 Q1	$1.75M	Sell	178,495 -8,622	-5%	-$84K	0.05%	266
2021 Q4	$1.81M	Buy	187,117 +176,529	+1,667%	+$1.72M	0.04%	339
2021 Q3	$103K	Sell	10,588 -497	-4%	-$4.8K	﹤0.01%	756
2021 Q2	$107K	Buy	+11,085	New	+$108K	﹤0.01%	805

Glazer Capital LLC's IBER Position: Q1 2023 in Review

Glazer Capital LLC sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 1,330,102 shares — an estimated $13.4M sold.

Glazer Capital LLC first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $13.4M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Glazer Capital LLC reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Glazer Capital LLC sold 1,330,102 Ibere Pharmaceuticals shares in Q1 2023, an estimated $13.4M.
Glazer Capital LLC first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Glazer Capital LLC's Ibere Pharmaceuticals position peaked at $13.4M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Glazer Capital LLC's 13F filing for Q1 2023, filed 15 May 2023.